Patients diagnosed with one of the following: low-grade appendiceal mucinous neoplasm, pseudomyxoma peritonei, appendiceal cancer with peritoneal carcinomatosis, colorectal cancer with peritoneal carcinomatosis
ECOG performance status \< 3
Candidate for grossly complete cytoreductive surgery
Life expectancy greater than 3 months
Adequate organ and marrow function
Ability to understand and the willingness to sign a written informed consent document
You may not be if
Any extra-abdominal metastases
Untreated lung metastases
Liver metastases not amenable to resection or ablation
Known brain metastases
Chemotherapy or radiotherapy within 4 weeks prior to entering the study
Presence of residual significant adverse events attributed to prior cancer treatment
Currently receiving any other investigational therapeutic agents
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Mitomycin C.
Pregnant or breast-feeding women
Uncontrolled ongoing illness
Clareo Health | Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC
